Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas Eigentler

Showing results (61-70 of 127) with videos related to

Pageof 13
Sort By:
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|July 27, 2020
Maja Ann Hofmann, Ulrike Keim, Agata Jagoda, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|June 6, 2013
Brief S2k guidelines--Cutaneous squamous cell carcinomaHelmut Breuninger, Thomas Eigentler, Friedrich Bootz, et al.
Cancers|June 24, 2022
Combination of Whole-Body Baseline CT Radiomics and Clinical Parameters to Predict Response and Survival in a Stage-IV Melanoma Cohort Undergoing ImmunotherapyFelix Peisen, Annika Hänsch, Alessa Hering, et al.
The Journal of Investigative Dermatology|September 30, 2011
CHEK2*1100delC and risk of malignant melanoma: Danish and German studies and meta-analysisMaren Weischer, Ida M Heerfordt, Stig E Bojesen, et al.
European Journal of Cancer (Oxford, England : 1990)|June 19, 2019
Efficacy of PD-1-based immunotherapy after radiologic progression on targeted therapy in stage IV melanomaSophia Kreft, Anja Gesierich, Thomas Eigentler, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|December 3, 2009
Depressive mood changes and psychiatric symptoms during 12-month low-dose interferon-alpha treatment in patients with malignant melanoma: results from the multicenter DeCOG trialSarah Heinze, Friederike Egberts, Susanne Rötzer, et al.
Immunotherapy|January 5, 2019
Immunotherapy plus surgery/radiosurgery is associated with favorable survival in patients with melanoma brain metastasisTeresa Amaral, Ioanna Tampouri, Thomas Eigentler, et al.
Journal of Cancer Research and Clinical Oncology|February 22, 2022
TMB and BRAF mutation status are independent predictive factors in high-risk melanoma patients with adjuvant anti-PD-1 therapyJulia Eckardt, Christopher Schroeder, Peter Martus, et al.
International Journal of Environmental Research and Public Health|July 27, 2022
eHealth Literacy in German Skin Cancer PatientsHenner Stege, Sara Schneider, Andrea Forschner, et al.
Plos One|August 17, 2019
Peripheral PD-1+CD56+ T-cell frequencies correlate with outcome in stage IV melanoma under PD-1 blockadeJonas Bochem, Henning Zelba, Teresa Amaral, et al.
Pageof 13

Showing results (61-70 of 127) with videos related to

Sort By:
Pageof 13
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|July 27, 2020
Maja Ann Hofmann, Ulrike Keim, Agata Jagoda, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|June 6, 2013
Brief S2k guidelines--Cutaneous squamous cell carcinomaHelmut Breuninger, Thomas Eigentler, Friedrich Bootz, et al.
Cancers|June 24, 2022
Combination of Whole-Body Baseline CT Radiomics and Clinical Parameters to Predict Response and Survival in a Stage-IV Melanoma Cohort Undergoing ImmunotherapyFelix Peisen, Annika Hänsch, Alessa Hering, et al.
The Journal of Investigative Dermatology|September 30, 2011
CHEK2*1100delC and risk of malignant melanoma: Danish and German studies and meta-analysisMaren Weischer, Ida M Heerfordt, Stig E Bojesen, et al.
European Journal of Cancer (Oxford, England : 1990)|June 19, 2019
Efficacy of PD-1-based immunotherapy after radiologic progression on targeted therapy in stage IV melanomaSophia Kreft, Anja Gesierich, Thomas Eigentler, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|December 3, 2009
Depressive mood changes and psychiatric symptoms during 12-month low-dose interferon-alpha treatment in patients with malignant melanoma: results from the multicenter DeCOG trialSarah Heinze, Friederike Egberts, Susanne Rötzer, et al.
Immunotherapy|January 5, 2019
Immunotherapy plus surgery/radiosurgery is associated with favorable survival in patients with melanoma brain metastasisTeresa Amaral, Ioanna Tampouri, Thomas Eigentler, et al.
Journal of Cancer Research and Clinical Oncology|February 22, 2022
TMB and BRAF mutation status are independent predictive factors in high-risk melanoma patients with adjuvant anti-PD-1 therapyJulia Eckardt, Christopher Schroeder, Peter Martus, et al.
International Journal of Environmental Research and Public Health|July 27, 2022
eHealth Literacy in German Skin Cancer PatientsHenner Stege, Sara Schneider, Andrea Forschner, et al.
Plos One|August 17, 2019
Peripheral PD-1+CD56+ T-cell frequencies correlate with outcome in stage IV melanoma under PD-1 blockadeJonas Bochem, Henning Zelba, Teresa Amaral, et al.
Pageof 13